Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib long-term extension in psoriatic arthritis
NCT01976364Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of tofacitinib oral solution in psoriatic arthritis (PsA), sponsored by Pfizer. Started Feb 2014; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01976364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01976364.